Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals reported a planned sale of 5,885 shares of its common stock under Rule 144. The shares, with an aggregate market value of $487,897.77, are expected to be sold on or about January 30, 2026 through Morgan Stanley Smith Barney on NASDAQ.
The seller acquired these 5,885 shares on January 29, 2026 via performance stock units granted under the company’s 2011 Equity Incentive Plan as compensation. During the prior three months, 8,977 Ionis common shares were also sold, generating gross proceeds of $674,621.55.
A shareholder of Ionis Pharmaceuticals has filed a notice to sell 6,988 shares of common stock through Morgan Stanley Smith Barney on 01/30/2026 on NASDAQ. The filing lists an aggregate market value of $580,049.03 for this planned sale.
The shares were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation. Over the prior three months, the same account sold 12,922 common shares for $971,992.84.
Ionis Pharmaceuticals insider plans additional stock sale under Rule 144. A person associated with Ionis plans to sell 62,970 shares of common stock through broker Morgan Stanley Smith Barney on or about 01/30/2026 on NASDAQ, with an aggregate market value of 5,223,748.59.
The shares come from performance stock units granted under the company’s 2011 Equity Incentive Plan and delivered as compensation on 01/29/2026. During the prior three months, the same broker sold 44,034 shares of Ionis common stock for gross proceeds of 3,294,623.88 for the same account.
Ionis Pharmaceuticals insider plans a Rule 144 stock sale. A holder intends to sell 6,179 shares of Ionis common stock through Morgan Stanley Smith Barney on or about 01/30/2026 on NASDAQ, with an aggregate market value of $512,905.75.
The shares were acquired on 01/29/2026 as performance stock units granted under Ionis’ 2011 Equity Incentive Plan and paid as compensation. The filer also reports a prior sale in the last three months of 9,191 common shares for gross proceeds of $697,045.44.
Ionis Pharmaceuticals has a Form 144 notice covering the planned sale of 6,179 shares of its common stock through Morgan Stanley Smith Barney on NASDAQ. The aggregate market value of these shares is $512,905.75.
The shares were acquired on 01/29/2026 as performance stock units (PSUs) granted under the company’s 2011 Equity Incentive Plan as compensation. Ionis had 161,137,930 common shares outstanding. During the prior three months, the same broker sold 23,463 and 9,884 Ionis shares, for gross proceeds of $1,856,324.51 and $744,660.56.
Ionis Pharmaceuticals has a planned sale of 6,179 shares of its common stock through Morgan Stanley Smith Barney on NASDAQ, with an approximate sale date of 01/30/2026 and an aggregate market value of 512,905.75. These shares were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan and paid as compensation.
The notice also reports that 9,302 common shares of Ionis were sold on 01/16/2026, generating gross proceeds of 703,138.18. The form includes a representation that the seller is not aware of any undisclosed material adverse information about Ionis’ current or prospective operations.
Ionis Pharmaceuticals executive Shannon L. Devers sold 3,977 shares of common stock on January 22, 2026 under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $81.3403 per share, with individual trades executed between $81.33 and $81.37. After this transaction, Devers beneficially owns 22,541 shares of Ionis Pharmaceuticals common stock in direct form.
An affiliate of IONS filed an amended notice of proposed sales of the issuer’s common stock under Rule 144. The filing covers a planned sale of 3,977 shares of common stock through broker Stifel Nicolaus & Company Inc., with an aggregate market value of $323,490.00, to be sold on or about 01/22/2026 on the Nasdaq market. These shares were acquired as restricted stock units from the issuer on 01/13/2026 as equity compensation, with payment dated 01/07/2026. The notice also lists prior sales in the last three months by Shannon Devers totaling several tranches of common stock, each with disclosed dates, amounts, and gross proceeds.
A shareholder has filed a notice of proposed sale of 3,977 shares of common stock through broker Stifel Nicolaus & Company on or about 01/22/2026, with the shares listed on Nasdaq. These shares were acquired on 01/13/2026 as restricted stock units from the issuer, with equity compensation recorded on 01/07/2026. The filing also notes that the same shareholder sold 44,199 shares of common stock on 01/07/2026 for gross proceeds of $3,756,915.00 and 16,777 shares on 11/25/2025 for gross proceeds of $1,342,160.00. The shareholder represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.
Ionis Pharmaceuticals shareholder has filed a notice of proposed sale under Rule 144 for 1,171 shares of common stock, with an aggregate market value of $93,680.00. The shares are to be sold through Morgan Stanley Smith Barney on or about 01/16/2026 on the NASDAQ exchange.
The securities were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, treated as compensation from Ionis Pharmaceuticals. The filing notes that total common shares outstanding are 161,137,930, providing context for the size of this planned sale relative to the company’s equity base.